Butabarbital | hsa00380 | Tryptophan metabolism | 4.14E-02 | 1 | Q16613 | AANAT | More | |
Butabarbital | hsa00500 | Starch and sucrose metabolism | 2.86E-02 | 2 | O43451, P46976 | MGAM, GYG1 | More | |
Butabarbital | hsa00730 | Thiamine metabolism | 1.75E-04 | 3 | Q9Y6K8, P05186, P24666 | AK5, ALPL, ACP1 | More | |
Butabarbital | hsa00770 | Pantothenate and CoA biosynthesis | 1.78E-02 | 2 | O95498, O95497 | VNN2, VNN1 | More | |
Butabarbital | hsa01240 | Biosynthesis of cofactors | 3.34E-02 | 3 | P05186, Q9Y6K8, O75911 | ALPL, AK5, DHRS3 | More | |
Butabarbital | hsa03008 | Ribosome biogenesis in eukaryotes | 4.94E-02 | 2 | P19784, P67870 | CSNK2A2, CSNK2B | More | |
Butabarbital | hsa03050 | Proteasome | 1.40E-02 | 1 | P55036 | PSMD4 | More | |
Butabarbital | hsa04024 | cAMP signaling pathway | 3.37E-02 | 3 | P63092, P26678, P61586 | GNAS, PLN, RHOA | More | |
Butabarbital | hsa04072 | Phospholipase D signaling pathway | 2.75E-02 | 3 | P61586, O14986, P63092 | RHOA, PIP5K1B, GNAS | More | |
Butabarbital | hsa04120 | Ubiquitin mediated proteolysis | 6.89E-03 | 5 | Q14145, Q13042, Q13191, Q15751, Q7Z6Z7 | KEAP1, CDC16, CBLB, HERC1, HUWE1 | More | |
Butabarbital | hsa04137 | Mitophagy - animal | 2.52E-02 | 2 | P19784, P67870 | CSNK2A2, CSNK2B | More | |
Butabarbital | hsa04310 | Wnt signaling pathway | 4.17E-03 | 3 | P61586, P19784, P67870 | RHOA, CSNK2A2, CSNK2B | More | |
Butabarbital | hsa04510 | Focal adhesion | 4.07E-02 | 3 | O14986, P61586, Q16363 | PIP5K1B, RHOA, LAMA4 | More | |
Butabarbital | hsa04520 | Adherens junction | 1.38E-04 | 3 | P19784, P67870, P61586 | CSNK2A2, CSNK2B, RHOA | More | |
Butabarbital | hsa04621 | NOD-like receptor signaling pathway | 4.31E-02 | 4 | P01375, P59665, P59666, P12838 | TNF, DEFA1; DEFA1B, DEFA3, DEFA4 | More | |
Butabarbital | hsa04640 | Hematopoietic cell lineage | 4.27E-02 | 4 | P08514, P14778, P01730, P13765 | ITGA2B, IL1R1, CD4, HLA-DOB | More | |
Butabarbital | hsa04659 | Th17 cell differentiation | 2.73E-02 | 4 | Q16539, P01730, P13765, P14778 | MAPK14, CD4, HLA-DOB, IL1R1 | More | |
Butabarbital | hsa04713 | Circadian entrainment | 4.94E-02 | 2 | P62873, P63092 | GNB1, GNAS | More | |
Butabarbital | hsa04723 | Retrograde endocannabinoid signaling | 4.94E-02 | 2 | P48169, P62873 | GABRA4, GNB1 | More | |
Butabarbital | hsa04724 | Glutamatergic synapse | 3.65E-02 | 2 | P63092, P62873 | GNAS, GNB1 | More | |
Butabarbital | hsa04726 | Serotonergic synapse | 2.52E-02 | 2 | P63092, P62873 | GNAS, GNB1 | More | |
Butabarbital | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
Butabarbital | hsa04972 | Pancreatic secretion | 3.65E-02 | 2 | P63092, P61586 | GNAS, RHOA | More | |
Butabarbital | hsa05032 | Morphine addiction | 9.04E-05 | 5 | P62873, P48169, P78334, P63092, P32298 | GNB1, GABRA4, GABRE, GNAS, GRK4 | More | |
Butabarbital | hsa05142 | Chagas disease | 2.26E-02 | 3 | P01375, P30679, P48023 | TNF, GNA15, FASLG | More | |
Butabarbital | hsa05143 | African trypanosomiasis | 2.72E-02 | 2 | P01375, P48023 | TNF, FASLG | More | |
Butabarbital | hsa05150 | Staphylococcus aureus infection | 1.83E-02 | 3 | P59665, P59666, P12838 | DEFA1; DEFA1B, DEFA3, DEFA4 | More | |
Butabarbital | hsa05163 | Human cytomegalovirus infection | 2.09E-02 | 4 | P62873, P61586, P63092, P61769 | GNB1, RHOA, GNAS, B2M | More | |
Butabarbital | hsa05171 | Coronavirus disease - COVID-19 | 4.47E-02 | 2 | Q9UHA3, O14786 | RSL24D1, NRP1 | More | |
Butabarbital | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
Butabarbital | hsa05332 | Graft-versus-host disease | 3.70E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
Butabarbital | hsa05340 | Primary immunodeficiency | 1.58E-02 | 3 | P01730, P11912, Q8WV28 | CD4, CD79A, BLNK | More | |